Jean-Christophe Rochet

List of Publications by Year in Descending Order

Source: https://exaly.com/author-pdf/5498836/jean-christophe-rochet-publications-by-year.pdf

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

80	9,324	35	85
papers	citations	h-index	g-index
85 ext. papers	10,263 ext. citations	7.2 avg, IF	5.63 L-index

#	Paper	IF	Citations
80	Shining a light on autophagy in neurodegenerative diseases. <i>Journal of Biological Chemistry</i> , 2021 , 101	43 7 .4	O
79	Hyperexcitability and Pharmacological Responsiveness of Cortical Neurons Derived from Human iPSCs Carrying Epilepsy-Associated Sodium Channel Nav1.2-L1342P Genetic Variant. <i>Journal of Neuroscience</i> , 2021 , 41, 10194-10208	6.6	3
78	Neuroprotective mechanisms of red clover and soy isoflavones in Parkinson's disease models. <i>Food and Function</i> , 2021 , 12, 11987-12007	6.1	O
77	Monitoring phagocytic uptake of amyloid linto glial cell lysosomes in real time. <i>Chemical Science</i> , 2021 , 12, 10901-10918	9.4	3
76	Localization of Fluorescent Targets in Deep Tissue With Expanded Beam Illumination for Studies of Cancer and the Brain. <i>IEEE Transactions on Medical Imaging</i> , 2020 , 39, 2472-2481	11.7	1
75	Calcein Release Assay to Measure Membrane Permeabilization by Recombinant Alpha-Synuclein. <i>Bio-protocol</i> , 2020 , 10,	0.9	6
74	AMPylation/Adenylylation of Alpha-synuclein by HYPE/FICD. <i>Bio-protocol</i> , 2020 , 10, e3760	0.9	O
73	DJ-1 can form Bheet structured aggregates that co-localize with pathological amyloid deposits. <i>Neurobiology of Disease</i> , 2020 , 134, 104629	7.5	10
72	Two C-terminal sequence variations determine differential neurotoxicity between human and mouse Bynuclein. <i>Molecular Neurodegeneration</i> , 2020 , 15, 49	19	3
71	Neuromelanin Modulates Heterocyclic Aromatic Amine-Induced Dopaminergic Neurotoxicity. <i>Toxicological Sciences</i> , 2020 , 173, 171-188	4.4	8
70	Assembly of Bynuclein aggregates on phospholipid bilayers. <i>Biochimica Et Biophysica Acta - Proteins and Proteomics</i> , 2019 , 1867, 802-812	4	20
69	Tuning a Bisphenol A Lateral Flow Assay Using Multiple Gold Nanosystems. <i>Particle and Particle Systems Characterization</i> , 2019 , 36, 1900133	3.1	3
68	Alpha-Synuclein Is a Target of Fic-Mediated Adenylylation/AMPylation: Possible Implications for Parkinson's Disease. <i>Journal of Molecular Biology</i> , 2019 , 431, 2266-2282	6.5	15
67	Novel Small Molecules Targeting the Intrinsically Disordered Structural Ensemble of Bynuclein Protect Against Diverse Bynuclein Mediated Dysfunctions. <i>Scientific Reports</i> , 2019 , 9, 16947	4.9	14
66	Acrolein-mediated neuronal cell death and alpha-synuclein aggregation: Implications for Parkinson's disease. <i>Molecular and Cellular Neurosciences</i> , 2018 , 88, 70-82	4.8	20
65	Selective dopaminergic neurotoxicity of three heterocyclic amine subclasses in primary rat midbrain neurons. <i>NeuroToxicology</i> , 2018 , 65, 68-84	4.4	17
64	Pikuni-Blackfeet traditional medicine: Neuroprotective activities of medicinal plants used to treat Parkinson's disease-related symptoms. <i>Journal of Ethnopharmacology</i> , 2017 , 206, 393-407	5	12

(2014-2017)

63	Lumbee traditional medicine: Neuroprotective activities of medicinal plants used to treat Parkinson's disease-related symptoms. <i>Journal of Ethnopharmacology</i> , 2017 , 206, 408-425	5	17	
62	A novel pathway for amyloids self-assembly in aggregates at nanomolar concentration mediated by the interaction with surfaces. <i>Scientific Reports</i> , 2017 , 7, 45592	4.9	34	
61	Dietary Phytochemicals in Neurodegenerative Disease 2017 , 361-391		4	
60	᠒ -Adrenoreceptor is a regulator of the ⊞ynuclein gene driving risk of Parkinson's disease. <i>Science</i> , 2017 , 357, 891-898	33.3	238	
59	Nortriptyline inhibits aggregation and neurotoxicity of alpha-synuclein by enhancing reconfiguration of the monomeric form. <i>Neurobiology of Disease</i> , 2017 , 106, 191-204	7.5	22	
58	Endosulfine-alpha inhibits membrane-induced Bynuclein aggregation and protects against Bynuclein neurotoxicity. <i>Acta Neuropathologica Communications</i> , 2017 , 5, 3	7.3	24	
57	Printed optics: phantoms for quantitative deep tissue fluorescence imaging: publisher's note. <i>Optics Letters</i> , 2016 , 41, 5575	3	1	
56	Printed optics: phantoms for quantitative deep tissue fluorescence imaging. <i>Optics Letters</i> , 2016 , 41, 5230-5233	3	10	
55	Effect of acidic pH on the stability of Bynuclein dimers. <i>Biopolymers</i> , 2016 , 105, 715-24	2.2	21	
54	Cu(II) promotes amyloid pore formation. <i>Biochemical and Biophysical Research Communications</i> , 2015 , 464, 342-7	3.4	7	
53	Direct Detection of Esynuclein Dimerization Dynamics: Single-Molecule Fluorescence Analysis. <i>Biophysical Journal</i> , 2015 , 108, 2038-47	2.9	36	
52	Effects of impaired membrane interactions on Bynuclein aggregation and neurotoxicity. <i>Neurobiology of Disease</i> , 2015 , 79, 150-63	7.5	55	
51	Hsp31 Is a Stress Response Chaperone That Intervenes in the Protein Misfolding Process. <i>Journal of Biological Chemistry</i> , 2015 , 290, 24816-34	5.4	23	
50	Overexpression of alpha-synuclein at non-toxic levels increases dopaminergic cell death induced by copper exposure via modulation of protein degradation pathways. <i>Neurobiology of Disease</i> , 2015 , 81, 76-92	7.5	47	
49	Expression and Transport of Esynuclein at the Blood-Cerebrospinal Fluid Barrier and Effects of Manganese Exposure. <i>ADMET and DMPK</i> , 2015 , 3, 15-33	1.3	13	
48	Neuroprotective effects of anthocyanin- and proanthocyanidin-rich extracts in cellular models of Parkinson?s disease. <i>Brain Research</i> , 2014 , 1555, 60-77	3.7	125	
47	Nepalese traditional medicine and symptoms related to Parkinson's disease and other disorders: Patterns of the usage of plant resources along the Himalayan altitudinal range. <i>Journal of Ethnopharmacology</i> , 2014 , 153, 178-89	5	18	
46	2-Amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP) is selectively toxic to primary dopaminergic neurons in vitro. <i>Toxicological Sciences</i> , 2014 , 140, 179-89	4.4	19	

45	Targeting the intrinsically disordered structural ensemble of Bynuclein by small molecules as a potential therapeutic strategy for Parkinson's disease. <i>PLoS ONE</i> , 2014 , 9, e87133	3.7	98
44	Role of Aberrant ⊞ynucleinMembrane Interactions in Parkinson Disease 2014 , 443-452		
43	⊞ynuclein misfolding assessed with single molecule AFM force spectroscopy: effect of pathogenic mutations. <i>Biochemistry</i> , 2013 , 52, 7377-86	3.2	33
42	Yeast reveal a "druggable" Rsp5/Nedd4 network that ameliorates	33.3	188
41	In vitro study of ⊞ynuclein protofibrils by cryo-EM suggests a Cu(2+)-dependent aggregation pathway. <i>Biophysical Journal</i> , 2013 , 104, 2706-13	2.9	30
40	Reusable photocatalytic titanium dioxide-cellulose nanofiber films. <i>Journal of Colloid and Interface Science</i> , 2013 , 399, 92-8	9.3	62
39	New insights into lysosomal dysfunction in Parkinson disease: an emerging role for ATP13A2. <i>Movement Disorders</i> , 2012 , 27, 1092	7	3
38	Molecular insights into Parkinson's disease. <i>Progress in Molecular Biology and Translational Science</i> , 2012 , 107, 125-88	4	59
37	Effect of spermidine on misfolding and interactions of alpha-synuclein. PLoS ONE, 2012, 7, e38099	3.7	43
36	Effect of single amino acid substitution on oxidative modifications of the Parkinson's disease-related protein, DJ-1. <i>Molecular and Cellular Proteomics</i> , 2012 , 11, M111.010892	7.6	18
35	Acid Bucosidase mutants linked to Gaucher disease, Parkinson disease, and Lewy body dementia alter Bynuclein processing. <i>Annals of Neurology</i> , 2011 , 69, 940-53	9.4	236
34	Esynuclein-induced tubule formation in lipid bilayers. <i>Journal of Physical Chemistry B</i> , 2011 , 115, 5886-9	33.4	35
33	Cyclin-G-associated kinase modifies Bynuclein expression levels and toxicity in Parkinson's disease: results from the GenePD Study. <i>Human Molecular Genetics</i> , 2011 , 20, 1478-87	5.6	47
32	Adsorption of alpha-synuclein on lipid bilayers: modulating the structure and stability of protein assemblies. <i>Journal of Physical Chemistry B</i> , 2010 , 114, 4070-81	3.4	36
31	PGC-1Ha potential therapeutic target for early intervention in Parkinson's disease. <i>Science Translational Medicine</i> , 2010 , 2, 52ra73	17.5	546
30	Compounds from an unbiased chemical screen reverse both ER-to-Golgi trafficking defects and mitochondrial dysfunction in Parkinson's disease models. <i>DMM Disease Models and Mechanisms</i> , 2010 , 3, 194-208	4.1	147
29	Alpha-synuclein is part of a diverse and highly conserved interaction network that includes PARK9 and manganese toxicity. <i>Nature Genetics</i> , 2009 , 41, 308-15	36.3	451
28	Path dependence of three-phase or two-phase end points in fluid binary lipid mixtures. <i>Journal of Physical Chemistry B</i> , 2009 , 113, 3431-6	3.4	5

(2003-2009)

27	Clustering of alpha-synuclein on supported lipid bilayers: role of anionic lipid, protein, and divalent ion concentration. <i>Biophysical Journal</i> , 2009 , 96, 540-51	2.9	53
26	Inhibition of ⊞ynuclein Aggregation by Antioxidants and Chaperones in Parkinson Disease. <i>Focus on Structural Biology</i> , 2009 , 175-206		4
25	Mechanisms of DJ-1 neuroprotection in a cellular model of Parkinson's disease. <i>Journal of Neurochemistry</i> , 2008 , 105, 2435-53	6	82
24	Methionine sulfoxide reductase A protects dopaminergic cells from Parkinson's disease-related insults. <i>Free Radical Biology and Medicine</i> , 2008 , 45, 242-55	7.8	85
23	The Parkinson's disease protein alpha-synuclein disrupts cellular Rab homeostasis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2008 , 105, 145-50	11.5	415
22	The use of cell-free systems to characterize parkinson's disease-related gene products 2008 , 597-627		1
21	Helical alpha-synuclein forms highly conductive ion channels. <i>Biochemistry</i> , 2007 , 46, 14369-79	3.2	106
20	Identification of the cysteine residue exposed by the conformational change in pig heart succinyl-CoA:3-ketoacid coenzyme A transferase on binding coenzyme A. <i>Biochemistry</i> , 2007 , 46, 10852	- <i>6ે</i> 3 ²	8
19	Destabilization of DJ-1 by familial substitution and oxidative modifications: implications for Parkinson's disease. <i>Biochemistry</i> , 2007 , 46, 5776-89	3.2	45
18	Effect of ions on the organization of phosphatidylcholine/phosphatidic acid bilayers. <i>Biophysical Journal</i> , 2007 , 93, 1630-8	2.9	28
17	Novel therapeutic strategies for the treatment of protein-misfolding diseases. <i>Expert Reviews in Molecular Medicine</i> , 2007 , 9, 1-34	6.7	93
16	Sirtuin 2 inhibitors rescue alpha-synuclein-mediated toxicity in models of Parkinson's disease. <i>Science</i> , 2007 , 317, 516-9	33.3	844
15	Errors in translation cause selective neurodegeneration. ACS Chemical Biology, 2006, 1, 562-6	4.9	4
14	Alpha-synuclein blocks ER-Golgi traffic and Rab1 rescues neuron loss in Parkinson's models. <i>Science</i> , 2006 , 313, 324-8	33.3	1084
13	Identification of rotenone-induced modifications in alpha-synuclein using affinity pull-down and tandem mass spectrometry. <i>Analytical Chemistry</i> , 2006 , 78, 2422-31	7.8	53
12	Small heat shock proteins protect against alpha-synuclein-induced toxicity and aggregation. <i>Biochemical and Biophysical Research Communications</i> , 2006 , 351, 631-8	3.4	148
11	Interactions among alpha-synuclein, dopamine, and biomembranes: some clues for understanding neurodegeneration in Parkinson's disease. <i>Journal of Molecular Neuroscience</i> , 2004 , 23, 23-34	3.3	154
10	The N-terminal repeat domain of alpha-synuclein inhibits beta-sheet and amyloid fibril formation. <i>Biochemistry</i> , 2003 , 42, 672-8	3.2	98

9	Annular alpha-synuclein protofibrils are produced when spherical protofibrils are incubated in solution or bound to brain-derived membranes. <i>Biochemistry</i> , 2002 , 41, 10209-17	3.2	327	
8	Vesicle permeabilization by protofibrillar alpha-synuclein: implications for the pathogenesis and treatment of Parkinson's disease. <i>Biochemistry</i> , 2001 , 40, 7812-9	3.2	599	
7	Kinetic stabilization of the alpha-synuclein protofibril by a dopamine-alpha-synuclein adduct. <i>Science</i> , 2001 , 294, 1346-9	33.3	968	
6	Amyloid fibrillogenesis: themes and variations. Current Opinion in Structural Biology, 2000, 10, 60-8	8.1	977	
5	Pig heart CoA transferase exists as two oligomeric forms separated by a large kinetic barrier. <i>Biochemistry</i> , 2000 , 39, 11291-302	3.2	15	
4	Inhibition of fibrillization and accumulation of prefibrillar oligomers in mixtures of human and mouse alpha-synuclein. <i>Biochemistry</i> , 2000 , 39, 10619-26	3.2	209	
3	Productive interactions between the two domains of pig heart CoA transferase during folding and assembly. <i>Biochemistry</i> , 1997 , 36, 8807-20	3.2	8	
2	Identification of glutamate 344 as the catalytic residue in the active site of pig heart CoA transferase. <i>Protein Science</i> , 1994 , 3, 975-81	6.3	28	
1	Phospholipid membranes promote the early stage assembly of Bynuclein aggregates		2	